Replimune Group (NASDAQ:REPL) Hits New 12-Month High After Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL) shares hit a new 52-week high during trading on Friday after BMO Capital Markets raised their price target on the stock from $14.00 to $18.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $15.46 and last traded at $15.34, with a volume of 794946 shares changing hands. The stock had previously closed at $11.05.

Several other equities research analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday. Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $17.00.

Insider Transactions at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Replimune Group during the 1st quarter valued at $147,000. Russell Investments Group Ltd. bought a new position in shares of Replimune Group during the first quarter valued at about $140,000. Vanguard Group Inc. boosted its holdings in shares of Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after purchasing an additional 32,555 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Replimune Group in the first quarter worth about $927,000. Finally, Clearbridge Investments LLC increased its holdings in Replimune Group by 2.7% during the 1st quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock valued at $2,271,000 after purchasing an additional 7,274 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The business has a 50-day simple moving average of $11.51 and a 200 day simple moving average of $9.67. The firm has a market cap of $1.09 billion, a P/E ratio of -5.22 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, analysts anticipate that Replimune Group, Inc. will post -3.02 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.